surmount-1 trial tirzepatide non-diabetic weight loss obesity Effect of in trial. (BMI: body mass index; CI: surmount-1 trial tirzepatide – Tirzepatide after intensive lifestyle intervention – In adults with obesity but

10.1097/00004714-199908000-00018 125 YangY.YuanL.WangK.LuD.MengF.XuD.et al (2024)

Tirzepatide and metformin together represent a powerful, evidence-based combination for managing type 2 diabetes when single-agent therapy fails to achieve glycemic targets

Specifically, it is the active ingredient in the following FDA-approved medications from Novo Nordisk: You might also see advertisements for compounded semaglutide, which is not FDA approved for safety and effectiveness

Insurance coverage is improving but still inconsistent

Diabetes, Obesity and Metabolism 24 (8), 15531564

Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials